Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
At a data cut-off of 37.3 months, EFS improved to 3.4 months for crenolanib, compared with 0.0 months for placebo.
Among a heavily pretreated, older adult population of patients with relapsed/refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML), revumenib was associated with a clinically ...
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31 ...
PRESS RELEASEAB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A ...
Black race is an independent prognostic factor for shorter survival in acute myeloid leukemia independent of cytogenetic ...
OS for Black patients was 57.8 months in those with a favorable ELN cytogenic RS, 14.2 months for those with intermediate RS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results